Latest Breaking News On - Corporate communications investors - Page 3 : comparemela.com

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). The filings were b

United statesSteve dabkowskiPaul hughesAustralian securities exchangeCorporate communications investorsMesoblast limited nasdaqDrug administrationJournal of the american college cardiologyMesoblast the companyUnited states foodCardiovascular surgery openMesoblast limitedPatients with heartAmerican collegePrivate securities litigation reform actCongenital heart disease

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesGreen bayMedical college of wisconsinSilviu itescuPaul hughesJohn levineSteve dabkowskiNational heartAustralian securities exchangeIcahn school of medicine at mount sinaiCollege of wisconsinSteering committeeNational marrow donor programSchool of pharmacyMesoblast the company

Mesoblast Partners With Blood and Marrow Transplant

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

New yorkUnited statesGreen bayMedical college of wisconsinPaul hughesSteve dabkowskiSilviu itescuJohn levineNational institutes of healthUnited states national institutes of healthCore transplant centers consortiaBlood instituteUnited states food drug administrationSchool of pharmacyAustralian securities exchangeSteering committee

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD – IT Business Net

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesGreen bayMedical college of wisconsinJohn levineSteve dabkowskiPaul hughesSilviu itescuCollege of wisconsinSchool of pharmacyAustralian securities exchangeEmmes companyMesoblast the companyNational marrow donor programNational institutes of healthMarrow transplant research

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiPaul hughesSilviu itescuDrug administrationCorporate communications investorsMarrow transplant clinical trials networkPharmaceuticals coUnited states food drug administrationMesoblast limited nasdaqAustralian securities exchangeQuarterly activity reportQuarter ended septemberChief executive silviu itescuUnited states foodEmergency investigational new drug